{"id":67813,"date":"2026-06-09T23:28:13","date_gmt":"2026-06-09T15:28:13","guid":{"rendered":"https:\/\/flcube.com\/?p=67813"},"modified":"2026-06-09T23:28:15","modified_gmt":"2026-06-09T15:28:15","slug":"everest-medicines-secures-asia-pacific-rights-to-vcare-pharmas-next-generation-p2y12-inhibitor-sumecigrel-in-3m-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67813","title":{"rendered":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#8217;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company <strong>Jiangsu Vcare PharmaTech Co., Ltd.<\/strong>, securing exclusive rights for <strong>clinical development, regulatory filing, and commercialization<\/strong> of <strong>sumecigrel<\/strong> across multiple Asia-Pacific regions including <strong>Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>Everest Medicines (HKG: 1952)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Jiangsu Vcare PharmaTech Co., Ltd.<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Southeast Asia, South Korea, Australia, Hong Kong, Macau, and Taiwan<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 20 million (USD 3 million)<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Milestone payments and commercial supply payments<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Clinical development, regulatory filing, and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-status\" class=\"wp-block-heading\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<h3 id=\"h-sumecigrel-characteristics\" class=\"wp-block-heading\">Sumecigrel Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class<\/strong>: Next-generation oral P2Y12 receptor antagonist<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Antiplatelet aggregation agent<\/li>\n\n\n\n<li><strong>Indications<\/strong>: Treatment and prevention of atherosclerotic thrombotic events including acute coronary syndrome (ACS), ischemic stroke (IS), and peripheral arterial disease (PAD)<\/li>\n\n\n\n<li><strong>Regulatory Classification<\/strong>: Category 1 innovative drug (China)<\/li>\n\n\n\n<li><strong>Global Development<\/strong>: Preparing for market filings in China, US, Europe, and additional regions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Portfolio Expansion<\/strong>: Strengthens Everest&#8217;s presence in high-prevalence cardiovascular therapeutic area<\/li>\n\n\n\n<li><strong>Regional Leadership<\/strong>: Establishes Everest as regional partner for next-generation antiplatelet therapy<\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong>: Leverages Everest&#8217;s established commercial infrastructure across Asia-Pacific markets<\/li>\n\n\n\n<li><strong>Development Efficiency<\/strong>: Accelerates regional development through experienced partner with proven regulatory expertise<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antiplatelet Market<\/strong>: Global P2Y12 inhibitor market valued at USD 8.7 billion in 2025 with established treatment guidelines<\/li>\n\n\n\n<li><strong>Unmet Needs<\/strong>: Next-generation agents aim to improve safety profile and reduce bleeding complications vs. current standard of care<\/li>\n\n\n\n<li><strong>Asia-Pacific Cardiovascular Burden<\/strong>: High and growing prevalence of atherosclerotic diseases across licensed territories<\/li>\n\n\n\n<li><strong>Regulatory Harmonization<\/strong>: Increasing alignment of regulatory requirements across Asia-Pacific regions facilitates coordinated development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>P2Y12 Inhibitor Competition<\/strong>: Established players include clopidogrel, ticagrelor, and prasugrel<\/li>\n\n\n\n<li><strong>Differentiation Opportunity<\/strong>: Next-generation profile potentially offers improved efficacy\/safety balance<\/li>\n\n\n\n<li><strong>Biosimilar Pressure<\/strong>: Limited impact on small molecule antiplatelet agents compared to biologic therapeutics<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Strong positioning in price-sensitive Asia-Pacific markets through local manufacturing partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding licensing agreements, clinical development, regulatory pathways, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and execution challenges in multi-territory development programs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,573],"class_list":["post-67813","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#039;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67813\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#039;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67813\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:28:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:28:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#8217;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal\",\"datePublished\":\"2026-06-09T15:28:13+00:00\",\"dateModified\":\"2026-06-09T15:28:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67813#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67813\",\"name\":\"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma's Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:28:13+00:00\",\"dateModified\":\"2026-06-09T15:28:15+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67813\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67813#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#8217;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma's Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67813","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma's Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal","og_description":"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).","og_url":"https:\/\/flcube.com\/?p=67813","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:28:13+00:00","article_modified_time":"2026-06-09T15:28:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67813#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67813"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#8217;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal","datePublished":"2026-06-09T15:28:13+00:00","dateModified":"2026-06-09T15:28:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67813"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","HKG: 1952","Vcare PharmaTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67813#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67813","url":"https:\/\/flcube.com\/?p=67813","name":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma's Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:28:13+00:00","dateModified":"2026-06-09T15:28:15+00:00","description":"Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical company Jiangsu Vcare PharmaTech Co., Ltd., securing exclusive rights for clinical development, regulatory filing, and commercialization of sumecigrel across multiple Asia-Pacific regions including Southeast Asia, South Korea, Australia, Hong Kong (China), Macau (China), and Taiwan (China).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67813#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67813"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67813#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma&#8217;s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67813"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67813\/revisions"}],"predecessor-version":[{"id":67814,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67813\/revisions\/67814"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}